Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;483(4):477-486.
doi: 10.1007/s00428-023-03604-8. Epub 2023 Jul 17.

MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective

Aadya N Kerkar  1 , Dheeraj Chinnam  2 , Aanchal Verma  3 , Nitin J Peters  4 , Nandita Kakkar  3 , Amita Trehan  5 , Minu Singh  5 , Kirti Gupta  6
Affiliations

MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective

Aadya N Kerkar et al. Virchows Arch. 2023 Oct.

Abstract

Background: Neuroblastoma (NB) is the most common extracranial solid tumour in childhood with a diverse clinical presentation and course. The early age of onset, high frequency of metastatic disease at diagnosis and tendency for spontaneous regression in infancy sets it apart from other childhood tumors. This heterogeneity is largely attributed to underlying genetic aberrations which are distinct in low-risk and high-risk NB. To this end, we sought to analyse our NB cases for the molecular alterations and find its correlation with clinical behaviour.

Methods: NB cases (n = 50) diagnosed over last 7 years were retrospectively analysed for MYCN amplification (fluorescent-in-situ hybridization), TERT rearrangements (qRT-PCR), ATRX mutations (immunohistochemistry). These findings were correlated with demographic profiles, histologic features and clinical outcome.

Results: Age ranged from 1 month to 30 years (mean 2.8 years) with male preponderance. Poorly differentiated subtype constituted the majority (64%), followed by differentiating (28%) and undifferentiated subtype (8%) which were equally distributed across all age groups. MYCN amplification, TERT-mRNA upregulation and ATRX mutations was observed in 30%, 42% and 24%, respectively. Cases with TERT-mRNA upregulation were distributed equally across all histological subtypes while those with ATRX mutations and MYCN amplification were frequent in poorly differentiated NB. ATRX mutation was mutually exclusive of TERT-mRNA upregulation and MYCN amplification. Kaplan-Meier analysis revealed significantly shorter overall and progression-free survival for tumors harboring MYCN amplification and TERT-mRNA upregulation, while that for ATRX mutant tumors was not significant.

Conclusions: Our results provide data indicating poor clinical outcome in NB carrying MYCN amplification and TERT-mRNA upregulation.

Keywords: ATRX mutation; MYCN amplification; Molecular alterations; Neuroblastoma; TERT rearrangements.

PubMed Disclaimer

Similar articles

  • Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M. Peifer M, et al. Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14. Nature. 2015. PMID: 26466568 Free PMC article.
  • MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
    Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kamiński MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MA. Zeineldin M, et al. Nat Commun. 2020 Feb 14;11(1):913. doi: 10.1038/s41467-020-14682-6. Nat Commun. 2020. PMID: 32060267 Free PMC article.
  • How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J, Kamijo T. Akter J, et al. Biomolecules. 2021 Jul 28;11(8):1112. doi: 10.3390/biom11081112. Biomolecules. 2021. PMID: 34439779 Free PMC article. Review.
  • Novel variants of the ATRX gene identified in MYCN non-amplified Neuroblastoma in Brazilian patients.
    Magalhães Gimenez T, Peralta VP, Giorgi RR, Morikawa K, Vince CC, Halley N, Siqueira SA, Bendit I, Cristofani LM, Filho VO, Novak EM. Magalhães Gimenez T, et al. Clinics (Sao Paulo). 2025 Apr 25;80:100652. doi: 10.1016/j.clinsp.2025.100652. eCollection 2025. Clinics (Sao Paulo). 2025. PMID: 40286729 Free PMC article.
  • Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A. Nakazawa A. Pathol Int. 2021 Apr;71(4):232-244. doi: 10.1111/pin.13085. Epub 2021 Mar 3. Pathol Int. 2021. PMID: 33657257 Review.
See all similar articles

Cited by

References

    1. London WB, Castleberry RP, Matthay KK et al (2005) Evidence for an age cut off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 23:6459–6465 - DOI - PubMed
    1. Carlsen NL (1990) How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 61:441–446 - DOI - PubMed - PMC
    1. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202–2211 - DOI - PubMed - PMC
    1. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma Lancet 369(9579):2106–2120 - DOI - PubMed
    1. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B et al (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86(2):364–372 - DOI - PubMed

LinkOut - more resources